Enavogliflozin for tricuspid valve insufficiency

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Sep 2023: Trial registered, NCT06027307
  2. 25 Oct 2023: Trial started, NCT06027307

The trials

NCT06027307: Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation

State
Under way
Phase
Phase 3
People
541 taking part
Started
25 Oct 2023
Primary completion
Jun 2027
Arms
Enavogliflozin
Results
None posted
  1. 7 Sep 2023: Trial registered
  2. 25 Oct 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as DWP16001 0.3mg.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.